The Beijing-3 strain was the main variant of the vaccine used in the Peoples Republic of China from 1968 until 2005.Three second-generation vaccines have entered markets since then: SA14-14-2, IC51 and ChimeriVax-JE. The live-attenuated SA14-14-2 strain was introduced in China in 1988. It is much cheaper than alternative vaccines, and is administered to 20 million Chinese children each year.A purified, formalin-inactivated, wholevirus vaccine known as IC51 (marketed in Australia and New Zealand as JESPECT and elsewhere as IXIARO) was licensed for use in the United States, Australia, and Europe during the spring of 2009. It is based on a SA14-14-2 strain and cultivated in Vero cells. In September 2012, the Indian firm Biological E. Limited launched an inactivated cell culture derived vaccine based on SA 14-14-2 strain which was developed in a technology transfer agreement with Intercell and is a thiomersal-free vaccine.Another vaccine, a live-attenuated recombinant chimeric virus vaccine developed using the Yellow fever virus known as ChimeriVax-JE (marketed as IMOJEV) was licensed for use in Australia in August 2010 and in Thailand in December 2012. References
External links
"Japanese Encephalitis Vaccine". Drug Information Portal. U.S. National Library of Medicine.
# If BMI is >30 kg/m2, central obesity can be assumed and waist circumference does not need to be measured

WHO
The World Health Organization (1999)  requires the presence of any one of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance, AND two of the following:

Blood pressure ≥ 140/90 mmHg
Dyslipidemia: triglycerides (TG) ≥ 1.695 mmol/L  and HDL cholesterol ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female)
Central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), or BMI > 30 kg/m2
Microalbuminuria: urinary albumin excretion ratio ≥ 20 µg/min or albumin:creatinine ratio ≥ 30 mg/g

EGIR
The European Group for the Study of Insulin Resistance (1999) requires insulin resistance defined as the top 25% of the fasting insulin values among nondiabetic individuals AND two or more of the following:
Central obesity: waist circumference ≥ 94 cm or 37 inches (male), ≥ 80 cm or 31.5 inches (female)
Dyslipidemia: TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L or treated for dyslipidemia
Blood pressure ≥ 140/90 mmHg or antihypertensive medication
Fasting plasma glucose ≥ 6.1 mmol/L

NCEP
The U.S. National Cholesterol Education Program Adult Treatment Panel III (2001) requires at least three of the following:
Central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 35 inches(female)
Dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dl)
Dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female)
Blood pressure ≥ 130/85 mmHg (or treated for hypertension)
Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl)

American Heart Association
There is confusion as to whether, in 2004, the American Heart Association and National Heart, Lung, and Blood Institute intended to create another set of guidelines or simply update the National Cholesterol Education Program definition.